Cargando…

Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas

Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual ABC transporter. It acts as an anion‐selective channel that drives osmotic fluid transport across many epithelia. In the gut, CFTR is crucial for maintaining fluid and acid‐base homeostasis, and its activity is tightly controll...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jonge, Hugo R., Ardelean, Maria C., Bijvelds, Marcel J. C., Vergani, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756540/
https://www.ncbi.nlm.nih.gov/pubmed/33113586
http://dx.doi.org/10.1002/1873-3468.13971
_version_ 1783626565078220800
author de Jonge, Hugo R.
Ardelean, Maria C.
Bijvelds, Marcel J. C.
Vergani, Paola
author_facet de Jonge, Hugo R.
Ardelean, Maria C.
Bijvelds, Marcel J. C.
Vergani, Paola
author_sort de Jonge, Hugo R.
collection PubMed
description Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual ABC transporter. It acts as an anion‐selective channel that drives osmotic fluid transport across many epithelia. In the gut, CFTR is crucial for maintaining fluid and acid‐base homeostasis, and its activity is tightly controlled by multiple neuro‐endocrine factors. However, microbial toxins can disrupt this intricate control mechanism and trigger protracted activation of CFTR. This results in the massive faecal water loss, metabolic acidosis and dehydration that characterize secretory diarrhoeas, a major cause of malnutrition and death of children under 5 years of age. Compounds that inhibit CFTR could improve emergency treatment of diarrhoeal disease. Drawing on recent structural and functional insight, we discuss how existing CFTR inhibitors function at the molecular and cellular level. We compare their mechanisms of action to those of inhibitors of related ABC transporters, revealing some unexpected features of drug action on CFTR. Although challenges remain, especially relating to the practical effectiveness of currently available CFTR inhibitors, we discuss how recent technological advances might help develop therapies to better address this important global health need.
format Online
Article
Text
id pubmed-7756540
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77565402020-12-28 Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas de Jonge, Hugo R. Ardelean, Maria C. Bijvelds, Marcel J. C. Vergani, Paola FEBS Lett Review Articles Cystic fibrosis transmembrane conductance regulator (CFTR) is an unusual ABC transporter. It acts as an anion‐selective channel that drives osmotic fluid transport across many epithelia. In the gut, CFTR is crucial for maintaining fluid and acid‐base homeostasis, and its activity is tightly controlled by multiple neuro‐endocrine factors. However, microbial toxins can disrupt this intricate control mechanism and trigger protracted activation of CFTR. This results in the massive faecal water loss, metabolic acidosis and dehydration that characterize secretory diarrhoeas, a major cause of malnutrition and death of children under 5 years of age. Compounds that inhibit CFTR could improve emergency treatment of diarrhoeal disease. Drawing on recent structural and functional insight, we discuss how existing CFTR inhibitors function at the molecular and cellular level. We compare their mechanisms of action to those of inhibitors of related ABC transporters, revealing some unexpected features of drug action on CFTR. Although challenges remain, especially relating to the practical effectiveness of currently available CFTR inhibitors, we discuss how recent technological advances might help develop therapies to better address this important global health need. John Wiley and Sons Inc. 2020-11-16 2020-12 /pmc/articles/PMC7756540/ /pubmed/33113586 http://dx.doi.org/10.1002/1873-3468.13971 Text en © 2020 The Authors. FEBS Letters published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Articles
de Jonge, Hugo R.
Ardelean, Maria C.
Bijvelds, Marcel J. C.
Vergani, Paola
Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title_full Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title_fullStr Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title_full_unstemmed Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title_short Strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
title_sort strategies for cystic fibrosis transmembrane conductance regulator inhibition: from molecular mechanisms to treatment for secretory diarrhoeas
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756540/
https://www.ncbi.nlm.nih.gov/pubmed/33113586
http://dx.doi.org/10.1002/1873-3468.13971
work_keys_str_mv AT dejongehugor strategiesforcysticfibrosistransmembraneconductanceregulatorinhibitionfrommolecularmechanismstotreatmentforsecretorydiarrhoeas
AT ardeleanmariac strategiesforcysticfibrosistransmembraneconductanceregulatorinhibitionfrommolecularmechanismstotreatmentforsecretorydiarrhoeas
AT bijveldsmarceljc strategiesforcysticfibrosistransmembraneconductanceregulatorinhibitionfrommolecularmechanismstotreatmentforsecretorydiarrhoeas
AT verganipaola strategiesforcysticfibrosistransmembraneconductanceregulatorinhibitionfrommolecularmechanismstotreatmentforsecretorydiarrhoeas